HL
XPH icon

HeadInvest LLC’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

HeadInvest LLC’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-470
Closed -$18.4K – 724
2023
Q3 		$18.4K Buy
+470
New +$19.9K ﹤0.01% 477

Other funds holding XPH

CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
Envestnet Portfolio Solutions
Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.28% 1-Year Est. Return

HeadInvest LLC's XPH Position: Q4 2023 in Review

HeadInvest LLC sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2023, closing a stake of 470 shares — an estimated $18.4K sold.

HeadInvest LLC first reported a position in XPH in Q3 2023 and held it in 1 quarter. The position peaked at $18.4K in Q3 2023. 73 funds tracked by Wall St. Rank hold XPH as of Q4 2023.

  • HeadInvest LLC reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2023 after selling out during the quarter.
  • HeadInvest LLC sold 470 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2023, an estimated $18.4K.
  • HeadInvest LLC first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q3 2023 and held it in 1 quarter.
  • HeadInvest LLC's State Street SPDR S&P Pharmaceuticals ETF position peaked at $18.4K in Q3 2023.
  • 73 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.